Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease.

Trial Profile

Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Everolimus (Primary) ; Aspirin; Cilostazol; Clopidogrel; Zotarolimus
  • Indications Coronary artery disease; Coronary artery restenosis; Embolism and thrombosis
  • Focus Therapeutic Use
  • Acronyms HOST-ASSURE
  • Most Recent Events

    • 16 Dec 2013 Planned end date changed from 1 Dec 2012 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
    • 09 Mar 2013 Primary endpoint results for the everolimus versus zotaralimus-eluting stent comparison presented at the 62nd Annual Scientific Session of the American College of Cardiology.
    • 25 Apr 2012 Results for the triple versus double-dose antiplatelet therapy comparison presented at the 61st Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top